INVESTIGADORES
BRUZZONE Ariana
congresos y reuniones científicas
Título:
CHARACTERIZATION OF ADRB2-MEDIATED ANTITUMORAL EFFECTS AND MECHANISMS OF ACTION OF β-BLOCKER PROPRANOLOL IN OSTEOSARCOMA
Autor/es:
SOLEMÓ L; SOBOL N; FERRERO MR; LLAVONA C; CAPOBIANCO C; BRUZZONE A; GOTTARDO MF; GARONA J
Lugar:
MAR DEL PLATA
Reunión:
Congreso; LXVII REUNION ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC); 2022
Institución organizadora:
SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA
Resumen:
Osteosarcoma (OSA) is still associated with limited response to standard-of-care therapy and alarmingly elevated mortality rates. Our group recently reported for the first time that PPN, a repurposed β1/2-adrenergic receptor (ADRB1/2) antagonist, was capable of reducing tumor-associated angiogenesis and xenograft aggressiveness using different OSA preclinical models. The objective of this work was to characterize PPN ADRB2-mediated effects and mechanisms of action on OSA growth, migration and response to chemotherapy. After confirming ADRB2 expression by RT-qPCR in MG-63 and U-2OS OSA cells, pro-mitogenic effects of ADRB agonists epinephrine and norepinephrine were associated with downstream activation of MAPK-associated signaling pathways, as evaluated by western blotting. ADRB2 knockdown by transfection with ADRB2-targeting siRNA reduced in vitro aggressiveness of OSA cells and impaired PPN cytostatic activity, confirming target specificity of the drug. As evaluated by flow cytometry, a significant arrest in the G0/G1 cell cycle phase of MG-63 and U-2OS cells was observed after 24 h treatment with PPN (50 µM), which was associated with a significant reduction in CCND1 gene expression, a key cell cycle regulator. OSA growth inhibition was not associated with apoptosis induction. β-blockade with PPN inhibited OSA cell chemotaxis, vasculogenic mimicry and capillary-like tube formation on Matrigel® coated substrates. Migration inhibition was linked to blockade of EGF-induced actin reorganization and stress fiber formation. After histological analysis, in vivo therapeutic benefits after addition of PPN (10 mg/kg i.p.) to cisplatin-based metronomic chemotherapy (2 mg/kg i.p.) correlated with reduced tumor mitotic index and increased necrosis. All results were significant at p